Compare Heron Therapeutics Inc (HRTX) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while JPMorgan Nasdaq Equity Premium Income ETF trades at $61.08 (market cap $44.49B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 654.2× Heron Therapeutics Inc's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and JPMorgan Nasdaq Equity Premium Income ETF for 65 Days on average.
| HRTX | JEPQ | |
|---|---|---|
Market Cap | $68.01M | $44.49B |
Volume | 1,891,941 | 5,681,789 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $61.46 |
52-Week Low | $0.27 | $53.77 |
Typical Hold Time | 35 Days | 65 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
JEPQ trades at $61.03, down 0.39% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong income generation through its covered-call strategy, with recent dividends ranging from $0.57 to $0.70 per share. Financial media coverage highlights JEPQ's 11% estimated annualized yield and suitability for retirement income, though analysts note the trade-off between high current income and limited price appreciation potential.
JEPQ offers exceptional current income for investors seeking monthly cash flow, with its covered-call strategy performing well in volatile markets. However, the ETF faces risks from market volatility dependence and potential principal erosion if yield chasing outweighs total return considerations. Institutional interest remains strong, with Envestnet increasing its position by 8.2% recently.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
